47 research outputs found
Zinc-mediated inhibition of human α<sub>1</sub>β<sub>2</sub> and α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>R signalling in <i>Xenopus</i> oocytes.
<p>(A) Representative trace of the inhibition mediated 100 μM Zn<sup>2+</sup> of the currents elicited by 10 μM GABA (EC<sub>80</sub>) through the α<sub>1</sub>β<sub>2</sub> GABA<sub>A</sub>R. (B) Representative trace of the inhibition mediated 100 μM Zn<sup>2+</sup> of the currents induced by 100 μM GABA (EC<sub>80</sub>) through the α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>R. (C) The degree of inhibition mediated by 100 μM Zn<sup>2+</sup> of GABA EC<sub>80</sub>-evoked currents in oocytes expressing α<sub>1</sub>β<sub>2</sub> mean ± S.E.M.; 77 ± 6.3%; N = 7and α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> (mean ± S.E.M.; 4.7 ± 4.6%; N = 6) GABA<sub>A</sub>Rs.</p
Functional properties of GABA at six human GABA<sub>A</sub>Rs expressed in <i>Xenopus</i> oocytes.
<p>Concentration-response curves of GABA at the α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub> (circle), α<sub>2</sub>β<sub>2</sub>γ<sub>2S</sub> (square), α<sub>3</sub>β<sub>2</sub>γ<sub>2S</sub> (triangle), α<sub>5</sub>β<sub>2</sub>γ<sub>2S</sub> (inverted triangle), α<sub>6</sub>β<sub>2</sub>δ (diamond) and α<sub>6</sub>β<sub>2</sub> (asterisk) GABA<sub>A</sub>Rs (means ± S.E.M.; N = 4–7).</p
Comparison of the functional efficacies of clobazam, <i>N</i>-desmethylclobazam, and clonazepam at α<sub>1,2,3,5</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>Rs with those of diazepam and zolpidem.
<p>(A) Potentiation of the response elicited by GABA EC<sub>20</sub> by 3 μM diazepam in Xenopus oocytes injected with cRNAs encoding for α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>2</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>3</sub>β<sub>2</sub>γ<sub>2S</sub> and α<sub>5</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>Rs in a subunit ratio of 1:1:1 (means ± S.E.M.; N = 2–4) (B) Potentiation of the response elicited by EC<sub>20</sub> GABA by 3 μM clobazam and 3 μM zolpidem in Xenopus oocytes injected with cRNAs encoding the α<sub>2</sub>β<sub>2</sub>γ<sub>2S</sub> GABA<sub>A</sub>R injected in a subunit ratio of 1:1:5 (means ± S.E.M.; N = 2).</p
. Functional properties of clobazam, <i>N</i>-desmethylclobazam and clonazepam at the human α<sub>6</sub>β<sub>2</sub>δ and α<sub>6</sub>β<sub>2</sub> GABA<sub>A</sub>Rs expressed in <i>Xenopus</i> oocytes.
<p>(A) Representative traces for various concentrations of clobazam (top), <i>N</i>-desmethylclobazam (middle) and clonazepam (bottom) co-applied with GABA EC<sub>20</sub> to oocytes expressing the α<sub>6</sub>β<sub>2</sub>δ GABA<sub>A</sub>R. The black bars represent applications of GABA EC<sub>20</sub> and of 300 M GABA that elicits maximal current through the receptor. The grey bars represent applications of various concentrations of clobazam, <i>N</i>-desmethylclobazam or clonazepam (a 30 s pre-incubation with the compound followed by co-application of the compound and GABA EC<sub>20</sub>). (B) Concentration-response relationships for clobazam (top), <i>N</i>-desmethylclobazam (middle) and clonazepam (bottom) at the α<sub>6</sub>β<sub>2</sub>δ GABA<sub>A</sub>R and for <i>N</i>-desmethylclobazam at the α<sub>6</sub>β<sub>2</sub> GABA<sub>A</sub>R (middle) in the presence of GABA EC<sub>20</sub> (means ± S.E.M.; N = 4–6).</p
Functional properties of GABA at the human α<sub>1</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>2</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>3</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>5</sub>β<sub>2</sub>γ<sub>2S</sub>, α<sub>6</sub>β<sub>2</sub>δ and α<sub>6</sub>β<sub>2</sub>GABA<sub>A</sub>Rs expressed in <i>Xenopus</i> oocytes.
<p>The EC<sub>50</sub> values are given in μM with pEC<sub>50</sub> ± S.E.M. values in brackets, and the Hill slopes (n<sub>H</sub> ± S.E.M.) and the numbers of experiments (N) are also given.</p
Chemical structures of clobazam, <i>N</i>-desmethylclobazam and clonazepam.
<p>Chemical structures of clobazam, <i>N</i>-desmethylclobazam and clonazepam.</p
Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5‑HT<sub>2A</sub> Receptor Agonists
Classical psychedelics
such as psilocybin, lysergic acid diethylamide
(LSD), and N,N-dimethyltryptamine (DMT) are showing
promising results in clinical trials for a range of psychiatric indications,
including depression, anxiety, and substance abuse disorder. These
compounds are characterized by broad pharmacological activity profiles,
and while the acute mind-altering effects can be ascribed to their
shared agonist activity at the serotonin 2A receptor (5-HT2AR), their apparent persistent therapeutic effects are yet to be decidedly
linked to activity at this receptor. We report herein the discovery
of 2,5-dimethoxyphenylpiperidines as a novel class of selective 5-HT2AR agonists and detail the structure–activity investigations
leading to the identification of LPH-5 [analogue (S)-11] as a selective 5-HT2AR agonist with
desirable drug-like properties
Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5‑HT<sub>2A</sub> Receptor Agonists
Classical psychedelics
such as psilocybin, lysergic acid diethylamide
(LSD), and N,N-dimethyltryptamine (DMT) are showing
promising results in clinical trials for a range of psychiatric indications,
including depression, anxiety, and substance abuse disorder. These
compounds are characterized by broad pharmacological activity profiles,
and while the acute mind-altering effects can be ascribed to their
shared agonist activity at the serotonin 2A receptor (5-HT2AR), their apparent persistent therapeutic effects are yet to be decidedly
linked to activity at this receptor. We report herein the discovery
of 2,5-dimethoxyphenylpiperidines as a novel class of selective 5-HT2AR agonists and detail the structure–activity investigations
leading to the identification of LPH-5 [analogue (S)-11] as a selective 5-HT2AR agonist with
desirable drug-like properties
Semisynthetic Analogues of Toxiferine I and Their Pharmacological Properties at α7 nAChRs, Muscle-Type nAChRs, and the Allosteric Binding Site of Muscarinic M<sub>2</sub> Receptors
A new series of analogues of the
calabash curare alkaloid toxiferine
I was prepared and pharmacologically evaluated at α7 and muscle-type
nAChRs and the allosteric site of muscarinic M<sub>2</sub> receptors.
The new ligands differ from toxiferine I by the absence of one (<b>2a</b>–<b>c</b>) or two (<b>3a</b>–<b>c</b>) hydroxy groups, saturation of the exocyclic double bonds,
and various N-substituents (methyl, allyl, 4-nitrobenzyl). At the
muscle-type nAChRs, most ligands showed similar binding to the muscle
relaxant alcuronium, indicating neuromuscular blocking activity, with
the nonhydroxylated analogues <b>3b</b> (<i>K</i><sub>i</sub> = 75 nM) and <b>3c</b> (<i>K</i><sub>i</sub> = 82 nM) displaying the highest affinity. At α7 nAChRs, all
ligands showed a moderate to low antagonistic effect, suggesting that
the alcoholic functions are not necessary for antagonistic action.
Compound <b>3c</b> exerted the highest preference for the muscle-type
nAChRs (<i>K</i><sub>i</sub> = 82 nM) over α7 (IC<sub>50</sub> = 21 μM). As for the allosteric site of M<sub>2</sub> receptors, binding was found to be dependent on N-substitution rather
than on the nature of the side chains. The most potent ligands were
the <i>N</i>-allyl analogues <b>2b</b> and <b>3b</b> (EC<sub>0.5,diss</sub> = 12 and 36 nM) and the <i>N</i>-nitrobenzyl derivatives <b>2c</b> and <b>3c</b> (EC<sub>0.5,diss</sub> = 32 and 49 nM). The present findings should help
delineate the structural requirements for activity at different types
of AChRs and for the design of novel selective ligands
Changes in cortical network activity induced by 7–9 cumulatively increasing concentrations of the functionally selective δ-GABA<sub>A</sub>R agonists THIP and Thio-THIP.
<p>The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p≤0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%).</p